🇺🇸 FDA
Pipeline program

GR-MD-02

GT-020

Phase 1 small_molecule completed

Quick answer

GR-MD-02 for Non-Alcoholic Steatohepatitis (NASH) is a Phase 1 program (small_molecule) at GALECTIN THERAPEUTICS INC with 1 ClinicalTrials.gov record(s).

Program details

Company
GALECTIN THERAPEUTICS INC
Indication
Non-Alcoholic Steatohepatitis (NASH)
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials